Use of a Highly Purified α1-Antitrypsin Standard to Establish Ranges for the Common Normal and Deficient α1-Antitrypsin Phenotypes

Diagnosis of the hereditary disorder alpha 1-antitrypsin (alpha 1AT) deficiency is critically dependent on quantification of serum levels of alpha 1AT, a 52-kDa antiprotease that serves to protect the lung from destruction by neutrophil elastase. Although the measurement of serum alpha 1AT levels is not difficult, there is no international standard for alpha 1AT, and investigators in the field recognize that widely used commercially available standards vary by as much as 50 percent. To establish accurate ranges for the common normal and deficient alpha 1AT phenotypes, the present study uses a purified alpha 1AT standard to quantify the alpha 1AT serum levels of 443 individuals with common normal and deficient alpha 1AT phenotypes, including MM, ZZ, SS, MZ, MS, and SZ. Based on the observed values, a statistical model was developed to generate predicted frequency distributions of alpha 1AT serum levels for each of these phenotypes. Based on these studies, the ranges (5th to 95th percentile) for alpha 1AT serum levels of the common phenotypes are: MM, 20 to 53 mumol/L; SS, 20 to 48 mumol/L; ZZ, 3.4 to 7.0 mumol/L; MZ, 15 to 42 mumol/L; MS, 18 to 52 mumol/L; and SZ, 10 to 23 mumol/L. This alpha 1AT standard and these ranges are being used for the National alpha 1-Antitrypsin Deficiency Registry organized under the auspices of the National Heart, Lung, and Blood Institute.

[1]  A. Buist,et al.  Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. , 1989, The American review of respiratory disease.

[2]  D. States,et al.  The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. , 1989, Chest.

[3]  R. Crystal,et al.  Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification. , 1989, The Journal of laboratory and clinical medicine.

[4]  R. Crystal,et al.  Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency , 1988 .

[5]  R. Crystal,et al.  Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. , 1988, The American review of respiratory disease.

[6]  R. Crystal,et al.  Molecular basis of alpha-1-antitrypsin deficiency. , 1988, The American journal of medicine.

[7]  R. Crystal,et al.  Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. , 1988, The American journal of medicine.

[8]  C. Chapuis-Cellier,et al.  [37] α1-antitrypsin , 1988 .

[9]  R. Crystal,et al.  Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. , 1987, The Journal of clinical investigation.

[10]  R. Crystal,et al.  Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. , 1987, The New England journal of medicine.

[11]  R. Crystal,et al.  Evaluation of "at risk" alpha 1-antitrypsin genotype SZ with synthetic oligonucleotide gene probes. , 1986, The Journal of clinical investigation.

[12]  P. Arnaud,et al.  The genetic polymorphism of alpha 2-HS glycoprotein: study by ultrathin-layer isoelectric focusing and immunoblot. , 1985, American journal of human genetics.

[13]  A Janoff,et al.  Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. , 1985, The American review of respiratory disease.

[14]  S. Eriksson The effect of tamoxifen in intermediate alpha 1-antitrypsin deficiency associated with the phenotype PiSZ. , 1983, Annals of clinical research.

[15]  R. Carrell,et al.  Structure and variation of human α1–antitrypsin , 1982, Nature.

[16]  K. Hirano,et al.  A simple one-step purification of human alpha 1-proteinase inhibitor by immunoadsorbent column chromatography. , 1981, Journal of biochemical and biophysical methods.

[17]  R. Crystal,et al.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. , 1981, The Journal of clinical investigation.

[18]  A. Johnson,et al.  Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978. , 1980, Human genetics.

[19]  J. Jeppsson,et al.  Properties of isolated human alpha1-antitrypsins of Pi types M, S and Z. , 1978, European journal of biochemistry.

[20]  C. Larsson,et al.  Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of alpha1-antitrypsin. , 1976, Scandinavian journal of respiratory diseases.

[21]  R. George,et al.  Comparison of commercially available radial immunodiffusion kits for the determination of serum alpha 1-antitrypsin concentrations. , 1975, The American review of respiratory disease.

[22]  J. Travis,et al.  Isolation and properties of human plasma α-1-proteinase inhibitor , 1974 .

[23]  J. Lieberman,et al.  Antitrypsin deficiency and abnormal protease inhibitor phenotypes. , 1973, Archives of environmental health.

[24]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[25]  M. Fagerhol,et al.  SERU Pi TYPES IN PATIENTS WITH PULMONARY DISEASES , 1969, Acta allergologica.

[26]  M. Fagerhol Quantitative Studies on the Inherited Variants of Serum α1-antitrypsin , 1969 .

[27]  J. Thorell,et al.  Effect of administration of a combined estrogen-progestin contraceptive on the level of individual plasma proteins. , 1968, Scandinavian journal of clinical and laboratory investigation.

[28]  A. Cohen,et al.  Estimation in Mixtures of Two Normal Distributions , 1967 .

[29]  E. L. Lehmann,et al.  Theory of point estimation , 1950 .